# VEL-101 to Prevent Rejection After Kidney Transplantation

> **NCT07290777** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Veloxis Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Transplantation, Kidney

## Interventions

- **DRUG:** Tacrolimus (TAC)
- **DRUG:** VEL-101

## Key facts

- **NCT ID:** NCT07290777
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290777, "VEL-101 to Prevent Rejection After Kidney Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07290777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*